08048035996
Leading Indian Pharma Exporter of WEGOVY FLEX 0.25mg Injection to Singapore – Tampines |Phoenix Exim

1. General Information

WEGOVY FlexTouch 0.25 mg is a prescription-only injectable medicine containing semaglutide. It is supplied in a pre-filled FlexTouch pen and is administered once weekly by subcutaneous injection. It is intended for weight management in eligible patients and should be used together with dietary changes and physical activity.

Manufacturer: Novo Nordisk
Active ingredient: Semaglutide
Strength: 0.25 mg
Dosage form: Solution for injection in pre-filled pen
Route: Subcutaneous injection
Frequency: Once weekly, as prescribed

2. Product Information

Each WEGOVY FlexTouch 0.25 mg pen contains semaglutide in a clear, colourless solution. The FlexTouch presentation contains multiple weekly doses, with the exact pack configuration depending on the market. The 0.25 mg strength is designed for the initial phase of treatment.

WEGOVY acts through GLP-1 receptors and helps regulate appetite and food intake. It is not intended to replace a balanced diet, physical activity, or professional medical care.

3. Uses of WEGOVY FlexTouch 0.25 mg

WEGOVY is used as an adjunct to diet and physical activity for:

  • Weight loss in eligible adults with obesity.
  • Weight management in adults who are overweight and have weight-related health problems.
  • Weight management in certain adolescents aged 12 years and above, according to applicable prescribing criteria.
  • In certain adults with established cardiovascular disease and overweight/obesity, it may also be used to reduce the risk of serious cardiovascular events, depending on the approved indication in the country.

Important: The 0.25 mg dose is primarily a treatment initiation dose, rather than the usual long-term maintenance dose. Dose escalation should be determined by a healthcare professional.

4. Benefits of This Medicine

Potential benefits of semaglutide treatment may include:

  • Supports clinically appropriate weight loss when combined with diet and physical activity.
  • Helps reduce appetite.
  • May increase feelings of fullness after eating.
  • May reduce hunger and food cravings.
  • Helps support long-term weight maintenance when treatment is continued as prescribed.
  • For eligible patients with established cardiovascular disease, Wegovy may reduce the risk of major cardiovascular events.

Individual results vary, and the medicine should be used only according to a healthcare professional's recommendation.

5. Side Effects of WEGOVY

Like all medicines, WEGOVY can cause side effects. Digestive symptoms are particularly common, especially when treatment is started or the dose is increased.

Possible side effects include:

  • Nausea
  • Vomiting
  • Diarrhoea
  • Constipation
  • Stomach or abdominal discomfort
  • Headache
  • Fatigue
  • Indigestion or heartburn
  • Dizziness

More serious reactions can occur less commonly, including pancreatitis, severe allergic reactions, gallbladder problems, dehydration-related kidney problems, and hypoglycaemia in particular circumstances.

6. Common Side Effects

The most commonly reported side effects are gastrointestinal, particularly:

  1. Nausea
  2. Diarrhoea
  3. Vomiting
  4. Constipation
  5. Abdominal pain or discomfort
  6. Headache
  7. Fatigue

If vomiting or diarrhoea is severe or persistent, dehydration can occur. Adequate fluid intake is important, and medical advice should be sought when symptoms are significant.

7. How to Use WEGOVY FlexTouch 0.25 mg

WEGOVY FlexTouch is normally administered once weekly, on the same day each week, according to the prescribed treatment schedule. It is injected subcutaneously, usually into the abdomen, thigh, or upper arm.

General administration points:

  • Check the pen label and prescribed strength before use.
  • Use a new disposable needle for each injection.
  • Follow the manufacturer's pen instructions carefully.
  • Do not share the pen or needles with another person.
  • Dispose of used needles safely.
  • Use the medicine only at the dose and frequency prescribed by your healthcare professional.

A healthcare professional should demonstrate the injection technique before the first use.

8. How WEGOVY Works

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a naturally occurring hormone involved in appetite regulation.

WEGOVY acts on GLP-1 receptors, including receptors involved in appetite control in the brain. This can increase feelings of fullness, decrease hunger and reduce food cravings, helping a person consume fewer calories.

9. Safety Advice

  • Use WEGOVY only under medical supervision.
  • Do not use it if you have had a serious allergic reaction to semaglutide or any ingredient in the product.
  • Tell your doctor if you have a history of pancreatitis, gallbladder disease, kidney problems, or significant gastrointestinal problems.
  • WEGOVY should not be used as a substitute for insulin.
  • Tell your healthcare professional about all medicines you take, particularly medicines that can lower blood glucose.
  • Seek urgent medical attention for severe, persistent abdominal pain, especially if it radiates to the back.
  • Avoid using a pen that has been frozen or exposed to unsuitable storage conditions.
  • Keep the pen and needles away from children.
  • Never share a pen or needle, even if the needle has been changed.
  • WEGOVY is not recommended during pregnancy; patients who become pregnant should contact their healthcare professional.
  • Because WEGOVY is a prescription medicine, treatment should be individualized by a qualified healthcare professional.

10. FAQs

Q1. What is WEGOVY FlexTouch 0.25 mg?
WEGOVY FlexTouch 0.25 mg is a semaglutide injection used as part of a weight-management program involving diet and physical activity.

Q2. What is the active ingredient?
The active ingredient is semaglutide.

Q3. How often is WEGOVY 0.25 mg taken?
It is generally administered once weekly according to the prescribed treatment schedule.

Q4. Is 0.25 mg the maintenance dose?
No. It is generally used as the initial dose to help the body adjust before gradual dose escalation.

Q5. Can WEGOVY be used without diet and exercise?
WEGOVY is intended to be used together with a reduced-calorie diet and increased physical activity.

Q6. Can I share my WEGOVY pen?
No. Pens and needles must never be shared between people.

Q7. What should I do if I experience severe side effects?
Contact a healthcare professional promptly. Severe or persistent abdominal pain, serious allergic symptoms, or significant dehydration require urgent medical assessment.

Q8. Is WEGOVY available in different strengths?
Yes. FlexTouch presentations include 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg strengths in markets where this presentation is authorized.

11. Substitute for WEGOVY FlexTouch 0.25 mg

There is no single universally appropriate substitute for WEGOVY. The alternative depends on the patient's indication, medical history, country, availability, and the prescriber's decision.

Medicines containing semaglutide or other GLP-1-based therapies may sometimes be considered alternatives, but they are not automatically interchangeable with WEGOVY. Examples of medicines that may be considered by healthcare professionals include semaglutide products marketed for different indications and other approved weight-management medicines.

Patients should not switch products, strengths, or doses without medical advice.

12. SEO Keywords

  • WEGOVY FlexTouch 0.25 mg Injection exporter
  • WEGOVY 0.25 mg Injection supplier from India
  • WEGOVY FlexTouch 0.25 mg supplier India
  • Semaglutide 0.25 mg injection exporter
  • WEGOVY 0.25 mg pre-filled pen exporter
  • WEGOVY FlexTouch 0.25 mg pharmaceutical exporter
  • WEGOVY 0.25 mg medicine exporter from Nagpur
  • Genuine WEGOVY FlexTouch 0.25 mg supplier
  • WEGOVY 0.25 mg injection wholesale supplier
  • Semaglutide injection pharmaceutical supplier India
  • WEGOVY FlexTouch 0.25 mg international supplier
  • WEGOVY 0.25 mg injection export from India
  • WEGOVY FlexTouch supplier to USA
  • WEGOVY 0.25 mg supplier to UK
  • WEGOVY 0.25 mg exporter to Australia
  • WEGOVY 0.25 mg supplier to Singapore
  • WEGOVY 0.25 mg exporter to Canada
  • WEGOVY 0.25 mg supplier to South Korea
  • WEGOVY 0.25 mg exporter to UAE
  • Semaglutide weight management injection supplier
  • WEGOVY FlexTouch pharmaceutical distributor
  • WEGOVY 0.25 mg prefilled injection supplier
  • Semaglutide FlexTouch exporter from India
  • WEGOVY medicine wholesale exporter
  • WEGOVY injection international pharmaceutical supplier
Aug 21st, 2026 12:48 PM

Keywords